Halozyme Therapeutics Inc (HALO)

08:57 AM

AMI Asset Management Corp Has $1.79 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

08:57 AM

07:00 AM

Sugar Maple Asset Management LLC Invests $373,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

07:00 AM

Jan 20, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Sees Large Growth in Short Interest - MarketBeat

Jan 20, 2025

Jan 19, 2025

Empirical Asset Management LLC Invests $1.09 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Jan 19, 2025

Jan 17, 2025

Bernzott Capital Advisors Invests $4.49 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Jan 17, 2025

Jan 17, 2025

Outlook Wealth Advisors LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Jan 17, 2025

Jan 16, 2025

Converting IV-drip Medications into Shots -January 16, 2025 at 12:29 pm EST - Marketscreener.com

Jan 16, 2025

Jan 15, 2025

(HALO) Technical Data - Stock Traders Daily

Jan 15, 2025

Jan 15, 2025

Research Analysts Offer Predictions for HALO FY2025 Earnings - MarketBeat

Jan 15, 2025

Jan 15, 2025

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance

Jan 15, 2025

Jan 15, 2025

Wells Fargo & Company Has Lowered Expectations for Halozyme Therapeutics (NASDAQ:HALO) Stock Price - Defense World

Jan 15, 2025

Jan 14, 2025

5 Biotech Stocks Worth Adding to Your Portfolio in 2025 - Zacks Investment Research

Jan 14, 2025

Jan 14, 2025

Q1 Earnings Forecast for HALO Issued By Leerink Partnrs - MarketBeat

Jan 14, 2025

Jan 13, 2025

Analyst Expectations For Halozyme Therapeutics's Future - Benzinga

Jan 13, 2025

Jan 13, 2025

Halozyme Therapeutics (NASDAQ:HALO) Price Target Cut to $57.00 by Analysts at Wells Fargo & Company - MarketBeat

Jan 13, 2025

Jan 13, 2025

Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $61.44 - MarketBeat

Jan 13, 2025

Jan 12, 2025

Piper Sandler Increases Halozyme Therapeutics (NASDAQ:HALO) Price Target to $53.00 - Defense World

Jan 12, 2025

Jan 12, 2025

HC Wainwright Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock - Defense World

Jan 12, 2025

Jan 11, 2025

HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up - MSN

Jan 11, 2025

Jan 11, 2025

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why - MSN

Jan 11, 2025

Jan 11, 2025

Halozyme raises 2025 guidance, announces $250M stock buyback - MSN

Jan 11, 2025

Jan 10, 2025

Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $53.00 - MarketBeat

Jan 10, 2025

Jan 10, 2025

Q3 EPS Estimate for Halozyme Therapeutics Lifted by Analyst - MarketBeat

Jan 10, 2025

Jan 09, 2025

Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock? - MSN

Jan 09, 2025

Jan 09, 2025

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Yahoo Finance

Jan 09, 2025

Jan 09, 2025

Q1 EPS Forecast for Halozyme Therapeutics Raised by Analyst - MarketBeat

Jan 09, 2025

Jan 09, 2025

Earnings call transcript: Halozyme Q3 2024 boosts guidance amid strong growth - Investing.com India

Jan 09, 2025

Jan 09, 2025

First Hawaiian Bank Purchases 20,700 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Jan 09, 2025

Jan 09, 2025

Everence Capital Management Inc. Purchases New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World

Jan 09, 2025

Jan 08, 2025

Halozyme Therapeutics (NASDAQ:HALO) Shares Gap UpTime to Buy? - MarketBeat

Jan 08, 2025

Jan 08, 2025

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia - Kilgore News Herald

Jan 08, 2025

Jan 08, 2025

Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings Guidance - MarketBeat

Jan 08, 2025

Jan 08, 2025

Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2024 Earnings Guidance - MarketBeat

Jan 08, 2025

Jan 08, 2025

Halozyme Therapeutics, Inc. Raises Earnings Guidance for the Full Year 2025 -January 08, 2025 at 07:00 am EST - Marketscreener.com

Jan 08, 2025

Jan 08, 2025

Halozyme Therapeutics (NASDAQ:HALO) Updates FY24 Earnings Guidance - MarketBeat

Jan 08, 2025

Jan 08, 2025

Halozyme Therapeutics (NASDAQ:HALO) Releases FY25 Earnings Guidance - MarketBeat

Jan 08, 2025

Jan 08, 2025

Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2024 - Marketscreener.com

Jan 08, 2025

Jan 08, 2025

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance - PR Newswire

Jan 08, 2025

Jan 07, 2025

Halozyme Therapeutics director Jeffrey Henderson sells $500,060 in stock - Investing.com India

Jan 07, 2025

Jan 07, 2025

Insider Sell: Jeffrey Henderson Sells 10,000 Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus.com

Jan 07, 2025

Jan 07, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson Sells 10,000 Shares - MarketBeat

Jan 07, 2025

Jan 07, 2025

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks - Yahoo Finance

Jan 07, 2025

Jan 07, 2025

Zacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical - Yahoo Finance

Jan 07, 2025

Jan 07, 2025

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance - The Malaysian Reserve

Jan 07, 2025

Jan 06, 2025

Halozyme Therapeutics (HALO) Shares Cross Above 200 DMA - Nasdaq

Jan 06, 2025

Jan 03, 2025

Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025 - Seeking Alpha

Jan 03, 2025

Dec 31, 2024

Halozyme: Recent Approvals Alter My Appetite (NASDAQ:HALO) - Seeking Alpha

Dec 31, 2024

Dec 30, 2024

FDA Approves BMS’ Opdivo Qvantig with Halozyme’s ENHANZE Technology - Contract Pharma

Dec 30, 2024